Shares in biotechnology group Horizon Therapeutics jumped by 15% after Amgen agreed to acquire it for $27.8bn, including debt, in “the largest healthcare merger of the year”, says The Wall Street Journal. The move
The year’s biggest biotech merger
Dec 16, 2022
1 minute
You’re reading a preview, subscribe to read more.
Start your free 30 days